NASDAQ:KA Kineta (KA) Stock Price, News & Analysis $0.64 -0.04 (-5.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.61▼$0.7050-Day Range$0.43▼$0.8352-Week Range$0.33▼$5.39Volume178,032 shsAverage Volume497,693 shsMarket Capitalization$7.88 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Kineta alerts: Email Address Kineta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,144.2% Upside$8.00 Price TargetShort InterestHealthy2.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.41) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKineta has received no research coverage in the past 90 days.Read more about Kineta's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.18% of the float of Kineta has been sold short.Short Interest Ratio / Days to CoverKineta has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kineta has recently increased by 8.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKineta does not currently pay a dividend.Dividend GrowthKineta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KA. Previous Next 1.9 News and Social Media Coverage News SentimentKineta has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kineta this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for KA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kineta insiders have not sold or bought any company stock.Percentage Held by Insiders23.70% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.32% of the stock of Kineta is held by institutions.Read more about Kineta's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kineta are expected to grow in the coming year, from ($1.41) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kineta is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kineta is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKineta has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kineta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Kineta Stock (NASDAQ:KA)Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.Read More KA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KA Stock News HeadlinesJuly 8, 2024 | globenewswire.comKineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesJuly 8, 2024 | prnewswire.comTuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | morningstar.comKineta Inc KAMay 15, 2024 | msn.comKA Stock Earnings: Kineta Misses EPS for Q1 2024May 15, 2024 | globenewswire.comKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate ActivitiesApril 18, 2024 | msn.comKineta (KA) Price Target Increased by 25.58% to 13.77April 9, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 8, 2024 | globenewswire.comKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialMarch 22, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMarch 1, 2024 | bizjournals.comKineta CEO laid off as cutbacks leave biotech with 4 employeesFebruary 29, 2024 | msn.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | globenewswire.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumSee More Headlines Receive KA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KA CUSIPN/A CIK1445283 Webwww.kinetabio.com Phone(206) 378-0400FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,059.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,100,000.00 Net MarginsN/A Pretax Margin-345.77% Return on Equity-1,044.95% Return on Assets-186.76% Debt Debt-to-Equity Ratio0.05 Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$5.44 million Price / Sales1.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book2.38Miscellaneous Outstanding Shares12,250,000Free Float9,350,000Market Cap$8.45 million OptionableNot Optionable Beta0.46 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Craig W. Philips (Age 63)President & Secretary Comp: $541.67kMr. Keith A. Baker (Age 57)Chief Financial Officer Comp: $485.75kDr. Thierry Guillaudeux Ph.D. (Age 56)Chief Scientific Officer Gary GentgesExecutive Vice President of Corporate DevelopmentMs. Pauline Kenny Esq. (Age 50)J.D., Advisor Comp: $349.72kKey CompetitorsLipocineNASDAQ:LPCNLianBioNASDAQ:LIANImmuCellNASDAQ:ICCCPluriNASDAQ:PLURVYNE TherapeuticsNASDAQ:VYNEView All CompetitorsInsidersRaymond J BartoszekBought 250 shares on 12/6/2023Total: $1,125.00 ($4.50/share)Raymond J BartoszekBought 1,000 shares on 12/4/2023Total: $4,330.00 ($4.33/share)Shawn IadonatoBought 900 shares on 11/28/2023Total: $2,997.00 ($3.33/share)Craig W PhilipsBought 3,000 shares on 11/28/2023Total: $9,810.00 ($3.27/share)Shawn IadonatoBought 10,000 shares on 9/20/2023Total: $25,000.00 ($2.50/share)View All Insider Transactions KA Stock Analysis - Frequently Asked Questions How have KA shares performed this year? Kineta's stock was trading at $3.63 at the start of the year. Since then, KA stock has decreased by 82.3% and is now trading at $0.6430. View the best growth stocks for 2024 here. How were Kineta's earnings last quarter? Kineta, Inc. (NASDAQ:KA) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.89) earnings per share for the quarter. How do I buy shares of Kineta? Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kineta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.